Natera (NTRA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.47
- Estimate
- -$0.53
- Surprise
- +12.0%
- Revenue (period 2026-06-30)
- $752.8M
- Score at report (before → after)
- 5.8 → 5.9/10
Revenue source: xbrl.
How the report landed
Natera (NTRA) reported a narrower loss than forecast — diluted EPS of -$0.47 against the -$0.53 estimate (a 12.0% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Hold (5.8/10) to Sell at 5.9/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates NTRA Sell at 5.2/10.
2 of the last 4 quarters beat the estimate; this quarter's +12.0% surprise compares with a +22.6% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Positive news sentiment (+0.67)
What argues against it
- Analyst target reached - limited upside remaining
- Near 52-week high (4.2% away)
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $328.93
- Price target
- $336.32
- Stop
- $309.47
- Upside to target
- +2.2%
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
NTRA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $47.41B
- P/E (fwd)
- -3196.3
- 52-week range
- $157.43–$343.18
- Off 52-week high
- 4.2%
- RSI (14)
- 47
- Volume vs avg
- 0.70×
- Score today
- 5.2/10